Condition: Solid Tumor · Advanced Cancer · Sponsor: Sun Yat-sen University
The purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.
This description comes directly from the study's public registry record.
Feng Wang, MD, PhD · +862087342635 · wangfeng@sysucc.org.cn
YING JIN, MD · +862087342479 · jinying1@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Cancer center of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| The Second Affiliated Hospital of Dalian Medical University | Dalian, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03810339